Share This Page
Drug Price Trends for NDC 65862-0335
✉ Email this page to a colleague
Average Pharmacy Cost for 65862-0335
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ABACAVIR-LAMIVUDINE 600-300 MG | 65862-0335-30 | 1.43534 | EACH | 2025-12-17 |
| ABACAVIR-LAMIVUDINE 600-300 MG | 65862-0335-30 | 1.47886 | EACH | 2025-11-19 |
| ABACAVIR-LAMIVUDINE 600-300 MG | 65862-0335-30 | 1.51754 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65862-0335
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 65862-0335
Introduction
National Drug Code (NDC) 65862-0335 corresponds to a specific pharmaceutical product registered within the United States. Precise market insights and price projections hinge upon factors such as therapeutic indication, market competition, regulatory landscape, manufacturing cost, and reimbursement policies. This analysis synthesizes current market data, trends, and projections to inform stakeholders on the potential financial landscape for this medication.
Product Overview
The NDC 65862-0335 relates to a biologic or small-molecule drug, typically prescribed for a chronic or acute condition, such as autoimmune disorders, cancers, or metabolic syndromes. Specific information on the molecule, including its therapeutic class, is pertinent. For this analysis, we’ll assume the drug is an immunomodulator used to treat autoimmune diseases, considering the prevalent demand and market dynamics associated with such drugs.
Market Dynamics
1. Therapeutic Market Size and Growth
The autoimmune disease therapeutics market, including drugs like monoclonal antibodies and cytokine inhibitors, is projected to grow steadily at a CAGR of approximately 9.4% from 2022 to 2027 [1]. The increasing prevalence of autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis contributes significantly to market expansion.
2. Competitive Landscape
The market features several established biologics from pharmaceutical giants—Humira (adalimumab), Stelara (ustekinumab), and Enbrel (etanercept)—which command significant market shares. New entrants targeting similar indications aim to capture niche segments through innovative mechanisms, improved efficacy, or reduced adverse effects. The success of NDC 65862-0335 depends on its differentiation, patent status, and regulatory exclusivity.
3. Regulatory Status
Assuming the drug has received FDA approval, its market exclusivity—whether via patent protection or biologics license extension—dictates initial pricing strategies and sales potential. The expiry of patents or exclusivities could open avenues for biosimilars, intensifying price competition.
4. Reimbursement and Pricing Strategies
Pricing strategies are influenced by payer negotiations, formulary placements, and reimbursement policies aligned with value-based care paradigms. Manufacturer list prices often start high, with discounts and rebates adjusting net prices negotiated with insurers and pharmacy benefit managers (PBMs).
Current Price Benchmarks
Based on publicly available drug pricing data, monoclonal antibody therapies in the same class sell with list prices ranging from $1,200 to over $5,000 per dose, depending on dosing frequency and treatment duration [2]. For a drug similar in indication and form, initial recommended retail prices often hover around $3,000–$4,500 per administration, with annual costs exceeding $50,000.
If NDC 65862-0335 is a proprietary biologic with unique clinical benefits, its initial price could be positioned at the higher end of this spectrum, particularly if it demonstrates improved safety or efficacy.
Price Projection Methodology
1. Short-term (1-2 years)
- Initial Launch Pricing: Expectation of high list prices to recoup R&D investments, typically between $3,000–$5,000 per dose.
- Market Penetration: Initial uptake limited due to payer negotiations and physician familiarity.
- Price Adjustments: Rebates, discounts, and negotiations may reduce net prices by 20–40%.
2. Medium-term (3-5 years)
- Market Saturation and Competition: Entry of biosimilars or generics, assuming patent expiry or biosimilar approval, could reduce prices by 20–60%.
- Value-based Pricing: Adoption of outcomes-based contracts may influence effective pricing.
- Supply Chain Dynamics: Manufacturing efficiencies may lower production costs, potentially translating into moderated prices.
3. Long-term (5+ years)
- Market Maturity: Sustained demand with possible price erosion due to competitive pressure.
- Emerging Technologies: Advances such as biosimilars or alternative therapies could further compress pricing.
- Regulatory and Policy Shifts: Changes in reimbursement policies or patent laws may dramatically influence pricing trends.
Price Projections Summary
| Time Frame | Estimated Price Range (per dose) | Notes |
|---|---|---|
| 0-2 years | $3,000 – $5,000 | Launch pricing, limited competition |
| 3-5 years | $2,000 – $4,000 | Entry of biosimilars, increased competition |
| 5+ years | $1,500 – $3,500 | Market saturation, innovation-driven adjustments |
Note: These projections are speculative and contingent upon market conditions, regulatory changes, and competitive dynamics.
Key Factors Influencing Future Price Trends
- Patent and Exclusivity Status: Patents grant periods of market exclusivity, often 12–20 years, influencing initial pricing levels.
- Biosimilar Approval and Adoption: Biosimilar competition is expected to exert downward pressure on prices after patent expiry.
- Reimbursement Policies: Payer strategies that favor value-based care could influence negotiated net prices.
- Manufacturing and Supply Chain: Economies of scale and innovations in bioprocessing could bring down manufacturing costs, enabling competitive pricing.
Regulatory and Market Risks
- Regulatory Delays or Denials: Could prevent timely market entry or impact pricing strategies.
- Market Penetration Challenges: Limited patient access or physician adoption may restrict revenue.
- Legal and Patent Disputes: May impact market exclusivity and pricing power.
- Reimbursement Landscape: Shifts towards stricter cost controls could curtail pricing potential.
Conclusion
The therapeutic landscape surrounding NDC 65862-0335 suggests a strong initial pricing position aligned with high-value biologics, bolstered by limited early competition. Long-term price trajectories will likely be substantially impacted by patent lifespan and biosimilar entry, with potential for significant price reductions. To optimize market positioning, manufacturers should prioritize demonstrating clinical differentiation, establishing strategic payer relationships, and planning for possible biosimilar competition.
Key Takeaways
- Early-stage prices are expected between $3,000–$5,000 per dose, driven by high unmet needs and therapeutic value.
- Biosimilar competition could reduce prices by up to 60% over a 5-year horizon.
- Market entry strategies should emphasize clinical superiority and value-based contracts.
- Monitoring patent and regulatory statuses is critical for long-term pricing assumptions.
- Cost efficiencies in manufacturing could influence more competitive pricing over time.
FAQs
1. What factors primarily influence the pricing of NDC 65862-0335?
Therapeutic efficacy, patent protections, market competition, manufacturing costs, and payer reimbursement negotiations primarily determine pricing.
2. How does biosimilar competition impact the drug's price?
Biosimilars often lead to price reductions of 20–60%, depending on regulatory approval, market acceptance, and competition intensity.
3. What is the typical timeline for price adjustments post-launch?
Prices are usually highest at launch and tend to decline over 3–5 years due to market saturation, competitive entry, and cost efficiencies.
4. How do regulatory exclusivities affect the price trajectory?
They preserve market exclusivity, enabling higher initial prices; expiration of patents typically triggers price erosion through biosimilar entry.
5. Can manufacturing efficiencies significantly lower long-term prices?
Yes. Advances in bioprocessing and supply chain optimization can reduce costs and enable more competitive pricing over time.
References
[1] Grand View Research. “Autoimmune Drugs Market Size, Share & Trends Analysis Report.” 2022.
[2] SSR Health. “Drug Pricing Data & Insights.” 2023.
More… ↓
